Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bendamustine + rituximab as initial treatment for indolent non-follicular non-Hodgkin lymphoma
2010-019248-37Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL) and 2 more, sponsored by Fondazione Italiana Linfomi. Primary endpoints: Overall response rate and Complete remission rate. Started Mar 2012; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Lymphoplasmacytic Lymphoma (LPL)Waldenström macroglobulinemia (WM)nodal marginal zone B-cell lymphoma (NMZL)
Beyond the preview
Go deeper on 2010-019248-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019248-37.